Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | THPO | P40225 | 1/20 | 0.51 |
| ▸ | NLN | Q9BYT8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27449710 | 0.88 | CYP3A4 (0.67) | CYP3A4SLC7A5HRH4HRH3MEN1 | |
| SCHEMBL15259275 | 0.88 | CYP3A4 (0.58) | CYP3A4SLC7A5HRH4HRH3MEN1 | |
| SCHEMBL30270561 | 0.88 | CYP3A4 (0.67) | CYP3A4SLC7A5HRH4HRH3MEN1 | |
| SCHEMBL12343824 | 0.88 | CYP3A4 (0.58) | CYP3A4SLC7A5HRH4HRH3MEN1 | |
| SCHEMBL18697423 | 0.86 | CYP3A4 (0.56) | CYP3A4SLC7A5HRH4HRH3MEN1 | |
| SCHEMBL17189358 | 0.86 | CYP3A4 (0.56) | CYP3A4SLC7A5HRH4HRH3MEN1 | |
| SCHEMBL12982022 | 0.86 | CYP3A4 (0.56) | CYP3A4SLC7A5HRH4HRH3MEN1 | |
| SCHEMBL12680071 | 0.84 | CYP3A4 (0.69) | CYP3A4SLC7A5HRH4HRH3MEN1 | |
| SCHEMBL23484143 | 0.83 | CYP3A4 (0.56) | CYP3A4SLC7A5HRH4HRH3MEN1 | |
| SCHEMBL31066572 | 0.83 | CYP3A4 (0.63) | CYP3A4SLC7A5HRH4HRH3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268880-B2 | Soft protease inhibitors and pro-soft forms thereof | TRUSTEES OF TUFTS COLLEGE (US) | 2012-09-18 | — | — | US | disclosed |
| US-20090124559-A1 | Soft Protease Inhibitors and Pro-Soft Forms Thereof | TRUSTEES OF TUFTS COLLEGE OFFICE OF TECHNOLOGY AND INDUSTRY COLLABORATION (US) | 2009-05-14 | — | — | US | disclosed |
| WO-2007100374-A9 | SOFT PROTEASE INHIBITORS AND PRO-SOFT FORMS THEREOF | TUFTS COLLEGE (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124559-A1 | Soft Protease Inhibitors and Pro-Soft Forms Thereof | PREP, DPP4, PEPD | CYP3A4 2816/4885SLC7A5 1655/4885HRH4 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.